The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

Maria Lucia Specchia, Maria Luisa Di Pietro, Chiara Cadeddu, Pietro Refolo, Gualtiero Ricciardi, Chiara De Waure, Silvio Capizzi, Francesco Di Nardo, Anna Maria Ferriero, Maria Assunta Veneziano, Maria Rosaria Gualano, Nicola Nicolotti, Antonella Sferrazza, Maria Daniela Gliubizzi, Giuseppe La Torre, Flavia Kheiraoui, L Mantovani, G Furneri, R Saulle

Research output: Contribution to journalArticle

Abstract

Streptococcus pneumoniae (Spn) is a common cause of Community-Acquired Pneumonia (CAP) and Invasive Pneunmococcal Diseases (IPD). Risk for infection increases in particular in elderly. The aim of the study was to evaluate the introduction of 13-valent conjugate pneumococcal vaccine (PCV13) among patients ≥50 years.
Original languageEnglish
Pages (from-to)284-285
Number of pages2
JournalEuropean Journal of Public Health
DOIs
Publication statusPublished - 2013

Keywords

  • health technology assessment

Fingerprint

Dive into the research topics of 'The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment'. Together they form a unique fingerprint.

Cite this